06 August 2021

KWM advises Zoetis on strategic acquisition of animal pharmaceutical manufacturer Jurox

King & Wood Mallesons is proud to have advised leading global animal healthcare company Zoetis on its acquisition of Australian-based animal pharmaceutical manufacturer Jurox.

The acquisition of Jurox will deliver Zoetis a valuable animal health portfolio, including leading animal anaesthetic Alfaxan®, and high-quality, local manufacturing operations in Australia as well as additional regional offices and subsidiaries in New Zealand, U.S., Canada and the UK, bolstering Zoetis’ product range and global footprint.

A KWM deal team led by M&A Partner Ros Anderson and Special Counsel Clifford Sandler advised Zoetis on all aspects of the transaction, which involved significant cross practice collaboration.

Partners Sharon Henrick and Patrick Gunning provided competition, IP and regulatory advice. Cross-border and Foreign Investment Review Board regulatory input came from Malcolm Brennan.

Commenting on the deal, KWM Partner Ros Anderson said:

“We’re delighted to have assisted Zoetis in securing this strategic acquisition.”

“Jurox brings Zoetis a high-quality portfolio of products, manufacturing capability and expansion opportunities, and that represents an exciting affirmation for Australia’s biomedical sector - this deal demonstrates the sector’s ability to turn scientific excellence into products which both make a difference and generate significant value commercially.”

Subject to the satisfaction of closing conditions and regulatory requirements, deal completion is expected in the first half of 2022.

Media contact

Share on LinkedIn Share on Facebook Share on Twitter
    You might also be interested in

    CBRE Hotels and King & Wood Mallesons are pleased to announce their involvement in the arrival of the Holiday Inn brand on West Perth’s Hay street, securing on behalf of the property owner, the...

    11 October 2021

    King & Wood Mallesons (KWM) is pleased to have acted for Lochard Energy to raise approximately A$1.3bn of new debt.

    28 September 2021

    King & Wood Mallesons is delighted to have assisted Lion on its strategic acquisition of the Fermentum Group.

    22 September 2021

    King & Wood Mallesons is pleased to have supported The Hospitals Contribution Fund of Australia Limited on its announced merger with Railway & Transport Health Fund Limited.

    17 September 2021

    This site uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Policy for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time.

    For more information on which cookies we use then please refer to our Cookie Policy.